Introduction: Down syndrome (DS) is associated with a higher risk of dementia. We hypothesize that amyloid beta (Aβ) in specific brain regions differentiates mild cognitive impairment in DS (MCI-DS) and test these hypotheses using cross-sectional and longitudinal data.
Methods: 18F-AV-45 (florbetapir) positron emission tomography (PET) data were collected to analyze amyloid burden in 58 participants clinically classified as cognitively stable (CS) or MCI-DS and 12 longitudinal CS participants.
Results: The study confirmed our hypotheses of increased amyloid in inferior parietal, lateral occipital, and superior frontal regions as the main effects differentiating MCI-DS from the CS groups. The largest annualized amyloid increases in longitudinal CS data were in the rostral middle frontal, superior frontal, superior/middle temporal, and posterior cingulate cortices.
Discussion: This study helps us to understand amyloid in the MCI-DS transitional state between cognitively stable aging and frank dementia in DS. The spatial distribution of Aβ may be a reliable indicator of MCI-DS in DS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233421 | PMC |
| http://dx.doi.org/10.1002/dad2.12013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High blood pressure is a significant risk factor for cardiovascular diseases and is linked to an increased risk of mild cognitive impairment (MCI). The lack of effective treatments for these conditions highlights the urgent need for novel therapeutic approaches. Recent research suggests that the gut microbiota-brain-gut axis plays a crucial role in the pathogenesis of hypertension and MCI by regulating the nervous, endocrine, and immune systems.
View Article and Find Full Text PDFA preliminary clinical study related to vestibular migraine and cognitive dysfunction.
Front Hum Neurosci
December 2024
The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Background And Purpose: Vestibular migraine (VM) is a common clinical disorder with a genetic predisposition characterized by recurrent episodes of dizziness/vertigo. Patients often complain of the presence of cognitive dysfunction manifestations such as memory loss, which causes great distress in daily life. In this study, we will explore the characteristics and possible risk factors of VM-related cognitive dysfunction by observing the cognitive function and vestibular function status of VM patients, laying the foundation for further exploration of the mechanisms of VM-related cognitive dysfunction.
View Article and Find Full Text PDFAlzheimer's disease (AD) is a progressive neurological condition characterized by a loss in cognitive functions, with no disease-modifying medication now available. It is crucial for early detection and treatment of Alzheimer's disease before clinical manifestation. The stage between cognitively healthy older persons and AD is known as mild cognitive impairment (MCI).
View Article and Find Full Text PDFThe apolipoprotein E ( ) ε4 allele is the strongest genetic risk factor for Alzheimer's disease (AD). ApoE is glycosylated with an O-linked Core-1 sialylated glycan at several sites, yet the impact and function of this glycosylation on AD biomarkers remains unclear. We examined apoE glycosylation in a cohort of cerebrospinal fluid (CSF, n=181) and plasma (n= 178) samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI) stratified into 4 groups: cognitively normal (CN), Mild Cognitive Impairment (MCI), progressors and non-progressors based on delayed word recall performance over 4 years.
View Article and Find Full Text PDFDynamic changes and prognostic value of glutathione S-transferase alpha in mild cognitive impairment and Alzheimer's disease.
Front Aging Neurosci
December 2024
Department of Geriatrics, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing, China.
Objectives: Glutathione S-transferase alpha (GSTα) is an important antioxidant enzyme closely associated with the onset and progression of neurodegenerative diseases. The alterations in GSTα protein levels associated with Alzheimer's disease and their impact on cognitive abilities remain unclear. Thus, investigating the fluctuations of GSTα protein levels in mild cognitive impairment (MCI) and Alzheimer's disease (AD) is essential.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!